18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: A study from the GOELAMS group

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 705-711

  Cahu, X ^a,c   Bodet Milin, C ^a   Brissot, E ^a   Maisonneuve, H ^b   Houot, R ^c   Morineau, N ^d   Solal Celigny, P ^e   Godmer, P ^f   Gastinne, T ^a   Moreau, P ^a   Moreau, A ^a   Lamy, T ^c,g   Kraber Bodere, F ^a,h,i   Le Gouill, S ^a,h  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Department of Hematology   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d Centre Catherine de Sienne   (France)

^e CENTRE JEAN BERNARD   (France)

^f Centre Hospitalier Departemental   (France)

^g INSERM U917   (France)

^h Team 12   (France)

ⁱ CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Positron emission tomography; T cell lymphoma; T NK neoplasm

Indexed keywords

ALEMTUZUMAB; CISPLATIN; CYTARABINE; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; PENTOSTATIN; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW BIOPSY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; SCINTISCANNING; T CELL LYMPHOMA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79952029114     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq415     Document Type: Article

References (30)

1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-4130.
2. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-2479.
3. Rodriguez J, Conde E, Gutierrez A et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652-657.
4. Chen AI, McMillan A, Negrin RS et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008; 14: 741-747.
5. Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106-113.
6. Le Gouill S, Milpied N, Buzyn A et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264-2271.
7. Terasawa T, Lau J, Bardet S et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27: 1906-1914.
8. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
9. Suh C, Kang YK, Roh JL et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 2008; 49: 1783-1789.
10. Khong PL, Pang CB, Liang R et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008; 87: 613-621.
11. Karantanis D, Subramaniam RM, Peller PJ et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 2008; 8: 94-99.
12. Berk V, Yildiz R, Akdemir UO et al. Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: utility of 18F-FDG PET in staging. Clin Nucl Med 2008; 33: 365-366.
13. Kako S, Izutsu K, Ota Y et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18: 1685-1690.
14. Bishu S, Quigley JM, Schmitz J et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007; 48: 1531-1538.
15. Hu-Bing W, Quan-Shi W, Ming-Fang W et al. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun 2010; 31: 195-200.
16. Hadithi M, Mallant M, Oudejans J et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006; 47: 1622-1627.
17. Swerdlow SH, Campo E, Lee Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: International Agency for Research on Cancer 2008.
18. A Predictive Model for Aggressive non-Hodgkin's Lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987-994.
19. Meignan M, Itti E, Bardet S et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol 2009; 27: 2739-2741.
20. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.
21. Mikhaeel NG, Timothy AR, O'Doherty MJ et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 2000; 39: 543-553.
22. Choi YH, Kang BW, Hong HS et al. The role of an early interim 18 F-FDG PET/CT for prediction of outcomes of patients with peripheral T cell lymphoma. ASH Annu Meet Abstr 2008; 112: 5272.
23. Kircher SM, Gurbuxani S, Smith SM. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer 2007; 38: 59-62.
24. Pro B, Nunez RF, Romaguera J et al. Achievement of FDG-PET negativity does not predict durable responses in T-cell lymphoma. ASH Annu Meet Abstr 2006; 108: 2404.
25. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-1260.
26. Tang B, Douglas-Nikitin V, Balon H et al. Exceptionally low metabolic activity in aggressive peripheral T-cell lymphoma. Nucl Med Commun 2009; 30: 838-840.
27. Mercadal S, Briones J, Xicoy B et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958-963.
28. Nickelsen M, Ziepert M, Zeynalova S et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2009; 20: 1977-1984.
29. Horning SJ, Juweid ME, Schöder H et al. Interim positron tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Group E3404 study. Blood 2010; 115: 775-777.
30. Lin C, Itti E, Haioun C et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48: 1626-1632.